Sino Biopharmaceutical Ltd (HK:1177)
:1177
Top Page
Sino Biopharmaceutical
(1177)
Select Model
Select Model
Rating:61Neutral
Price Target:
HK$7.50
▲(18.48% Upside)
Action:ReiteratedDate:10/24/25
The overall score of 61 for HK:1177 is primarily driven by strong financial performance, with solid profitability and cash flow growth. However, bearish technical indicators and a high P/E ratio weigh on the score, reflecting potential downside risks in momentum and valuation.
Positive Factors
Strong Profit Margins
High gross and net profit margins indicate efficient cost management and enhanced profitability, supporting long-term financial health.
Negative Factors
Cash Flow Transparency Concerns
Lack of cash flow data creates uncertainty about cash generation capabilities, potentially impacting financial planning and stability.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Profit Margins
High gross and net profit margins indicate efficient cost management and enhanced profitability, supporting long-term financial health.
Read all positive factors
Sino Biopharmaceutical (1177) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$113.21B
Dividend Yield1.4%
Average Volume (3M)114.93M
Price to Earnings (P/E)43.8
Beta (1Y)1.01
Revenue Growth13.69%
EPS Growth50.71%
CountryHK
Employees24,379
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.01
Shares Outstanding18,760,717,000
10 Day Avg. Volume98,005,928
30 Day Avg. Volume114,926,811
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.63
Price to Sales (P/S)1.81
P/FCF Ratio9.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$8.54Price Target Upside34.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)0.23
Revenue Forecast (FY)HK$36.03B
Sino Biopharmaceutical Business Overview & Revenue Model
Company Description
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medi...
How the Company Makes Money
Sino Biopharmaceutical generates revenue through multiple key streams, primarily from the sale of prescription drugs and OTC products. The company's revenue model is supported by a robust pipeline of innovative therapies, which contributes to its ...
Sino Biopharmaceutical Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
70
Positive
Cash Flow
80
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 30.57B | 28.87B | 26.20B | 26.03B | 26.86B | 23.65B |
| Gross Profit | 24.99B | 23.53B | 21.21B | 21.54B | 21.53B | 18.46B |
| EBITDA | 6.11B | 6.11B | 6.98B | 6.69B | 19.87B | 5.66B |
| Net Income | 3.87B | 3.50B | 2.33B | 2.54B | 14.61B | 2.77B |
Balance Sheet | ||||||
| Total Assets | 74.89B | 65.41B | 63.60B | 64.06B | 60.54B | 47.21B |
| Cash, Cash Equivalents and Short-Term Investments | 19.82B | 14.60B | 14.12B | 16.92B | 15.79B | 16.43B |
| Total Debt | 11.96B | 9.78B | 12.58B | 13.98B | 12.12B | 14.21B |
| Total Liabilities | 29.12B | 22.63B | 25.43B | 26.12B | 22.81B | 24.79B |
| Stockholders Equity | 33.37B | 31.96B | 30.47B | 29.75B | 30.29B | 16.75B |
Cash Flow | ||||||
| Free Cash Flow | 2.89B | 5.22B | 4.36B | 4.56B | 3.47B | 3.47B |
| Operating Cash Flow | 3.16B | 6.62B | 6.07B | 6.27B | 5.37B | 5.33B |
| Investing Cash Flow | -7.29B | -1.71B | -756.98M | -4.07B | -2.52B | -7.85B |
| Financing Cash Flow | 1.58B | -6.32B | -6.55B | -3.19B | -3.23B | 2.23B |
Sino Biopharmaceutical Technical Analysis
Positive
6.33
Price Trends
6.28
Positive
6.53
Negative
6.87
Negative
Market Momentum
-0.05
Negative
56.88
Neutral
80.48
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1177, the sentiment is Positive. The current price of 6.33 is above the 20-day moving average (MA) of 6.03, above the 50-day MA of 6.28, and below the 200-day MA of 6.87, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 56.88 is Neutral, neither overbought nor oversold. The STOCH value of 80.48 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1177.
Sino Biopharmaceutical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$64.41B | 9.63 | 14.85% | 0.95% | 7.51% | 44.09% | |
66 Neutral | HK$27.73B | 34.57 | 25.67% | ― | 2.57% | 18.79% | |
61 Neutral | HK$113.21B | 43.78 | 11.85% | 1.40% | 13.69% | 50.71% | |
61 Neutral | HK$158.77B | -762.50 | 4.82% | ― | 52.78% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$40.58B | -22.62 | -14.53% | ― | 38.56% | 48.26% | |
45 Neutral | HK$129.42B | -84.52 | -14.40% | ― | 33.46% | -7.60% |
* Healthcare Sector Average
HK:1177
Sino Biopharmaceutical
6.33
2.96
87.67%
HK:1801
Innovent Biologics
91.50
49.45
117.60%
HK:1530
3SBio
25.38
14.27
128.44%
HK:9926
Akeso, Inc.
140.50
73.25
108.92%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
26.38
13.18
99.85%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
76.60
50.50
193.49%
Sino Biopharmaceutical Corporate Events
Sino Biopharm Advances First-in-Class ROCK2 Inhibitor TDI01 Into Global First Phase III IPF Trial
Dec 31, 2025
Sino Biopharmaceutical has announced completion of enrollment of the first patient in a Phase III clinical trial for TDI01, its independently developed, highly selective ROCK2 inhibitor for idiopathic pulmonary fibrosis (IPF), marking the first dr...
Sino Biopharm’s Oral Psoriasis Drug TQH3906 Delivers Biologic-Like Efficacy in Phase II Trial
Dec 28, 2025
Sino Biopharmaceutical has reported positive Phase II clinical trial results for TQH3906, a Category 1 innovative oral TYK2/JAK1 JH2 allosteric inhibitor developed in-house for the treatment of moderate-to-severe plaque psoriasis. The randomized, ...
Sino Biopharmaceutical’s Culmerciclib Capsule Gains Approval for Breast Cancer Treatment
Dec 12, 2025
Sino Biopharmaceutical Limited announced that its self-developed drug, culmerciclib capsule, has been approved by the China National Medical Products Administration for marketing. This innovative drug, used in combination with fulvestrant, targets...
Sino Biopharmaceutical’s Oral GLP-1 Drug Approved for Clinical Trials
Dec 4, 2025
Sino Biopharmaceutical Limited has received approval from both the China National Medical Products Administration and the United States Food and Drug Administration for the clinical trial of its innovative drug, TQF3250, an orally administered GLP...
Sino Biopharmaceutical’s Rotigotine Patch Gains Approval for Parkinson’s Treatment
Dec 3, 2025
Sino Biopharmaceutical Limited has announced the approval of its Rotigotine Patch by the National Medical Products Administration of China for the treatment of early idiopathic Parkinson’s disease. This approval signifies a major advancement...
Sino Biopharmaceutical Advances Pain Management with Innovative Analgesic Trial
Dec 1, 2025
Sino Biopharmaceutical Limited has announced the successful enrollment of the first patient in the Phase I clinical trial for TRD208, a first-in-class, non-opioid, multi-target, multi-modal analgesic developed by the company. TRD208 is expected to...
Sino Biopharmaceutical’s LM-350 Receives Clinical Trial Approval in China
Nov 18, 2025
Sino Biopharmaceutical Limited announced that its innovative drug, LM-350 ‘CDH17 ADC’, has received clinical trial approval from China’s National Medical Products Administration. This approval marks a significant step in addressi...
Sino Biopharmaceutical’s Culmerciclib Shows Promising Results in Phase III Breast Cancer Study
Oct 20, 2025
Sino Biopharmaceutical has announced positive interim results from its Phase III clinical study of culmerciclib, a CDK2/4/6 inhibitor, in combination with fulvestrant for the first-line treatment of HR+/HER2-advanced breast cancer. The study, pres...
Sino Biopharmaceutical’s TQ-B3234 Gains Breakthrough Therapy Designation
Oct 15, 2025
Sino Biopharmaceutical Limited announced that its new drug, TQ-B3234, a selective MEK1/2 inhibitor, has been included in the Breakthrough Therapy Designation process by the Center for Drug Evaluation of China’s National Medical Products Admi...
Sino Biopharmaceutical’s TQB2102 Gains Breakthrough Designation in China
Oct 13, 2025
Sino Biopharmaceutical Limited announced that its drug TQB2102, a HER2 bispecific antibody-drug conjugate, has been included in China’s Breakthrough Therapeutic Designation process. This inclusion is expected to expedite the drug’s app...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.